ADC Therapeutics Medical Information Hub

Investigational Loncastuximab – LOTIS-5 Clinical Trial

Medical Information

Product: Loncastuximab Tesirine

{diffuse large B-cell lymphoma, DLBCL, gemcitabine, LOTIS 5, oxaliplatin, R-GEMOX, rituximab, }

Loncastuximab (ZYNLONTA) – Bulky Disease and Burkitt Lymphoma

Medical Information

Product: Loncastuximab Tesirine

{bulky, burkitt, burkitt lymphoma, }

Loncastuximab (ZYNLONTA) – Calculating Dose Based on ABW

Medical Information

Product: Loncastuximab Tesirine

{ABW, Adjusted body weight, BMI, body mass index, conversion, convert, dosage, dose, dosing, obese, obesity, overweight, weight, }

Loncastuximab (ZYNLONTA) – CD19 Expression, Response and Treatment

Medical Information

Product: Loncastuximab Tesirine

{CAR-T,exploratory, CD19, CD19 expression, chimeric antigen receptor T-cell, immunophenotypic, }

Loncastuximab (ZYNLONTA) – Concomitant Use with Vaccines

Medical Information

Product: Loncastuximab Tesirine

{Inactivated, Inactivated vaccine, Influenza, Live vaccine, Live vaccines, Pneumococcal, }

Loncastuximab (ZYNLONTA) – Cough Incidence

Medical Information

Product: Loncastuximab Tesirine

{Cough, Pneumonitis, Pulmonary edema, }

Loncastuximab (ZYNLONTA) – Drug Interactions

Medical Information

Product: Loncastuximab Tesirine

{BCRP, bile salt export pump, bilesalt export pump, breast cancer resistance protein, BSEP, CYP, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A4/5, CYP3A5, cytochrome, cytochrome P450, drug-drug, drug-interactions, glycoprotein, interactions, MATE, MATE1, MATE2-K, multi-antimicrobial extrusion, multiantimicrobial extrusion, OAT, OAT1, OAT2, OAT3, OATP, OATP1B1, OATP1B3, organic anion transporter, organic anion-transporting polypeptide, p-glycoprotein, p-gp, P450, }

Loncastuximab (ZYNLONTA) – Edema and Effusion Incidence & Management

Medical Information

Product: Loncastuximab Tesirine

{abdomen, adverse, AE, ascites, bloat, bloating, dexamethasone, diuretic, edema, effusion, fluid overload, oedema, pericardial, pericardiocentesis, pericarditis, pleurocentesis, pleuropericardial, pre-medication, premedication, reaction, reactions, spironolactone, swelling, TEAE, toxicities, toxicity, }

Loncastuximab (ZYNLONTA) – Extravasation Incidence and Management

Medical Information

Product: Loncastuximab Tesirine

{Extravasation, Injection site, IV infiltration, Pain, Subcutaneous, Subcutaneous infiltration, swelling, Tissue, Tissue damage, Ulcer, Ulceration, }

Loncastuximab (ZYNLONTA) – Hypersensitivity Incidence & Management

Medical Information

Product: Loncastuximab Tesirine

{Anaphylaxis, dexamethasone, Diphenhydramine, Hypersensitivity, Infusion-related, Methylprednisolone, prophylaxis, Ranitidine, }

Loncastuximab (ZYNLONTA) – Infection Prophylaxis

Medical Information

Product: Loncastuximab Tesirine

{infection, infection prophylaxis, prophylactic use, prophylaxis, }

Loncastuximab (ZYNLONTA) – Infusion Line of Administration

Medical Information

Product: Loncastuximab Tesirine

{administration, catheter, central, central device, central line, device, peripheral, peripheral device, peripheral line, Peripherally inserted central catheter, PICC, }

Loncastuximab (ZYNLONTA) – Latex Content

Medical Information

Product: Loncastuximab Tesirine

{latex, latex-free, }

Loncastuximab (ZYNLONTA) – LOTIS-2 Subgroup Analysis

Medical Information

Product: Loncastuximab Tesirine

{age, and any prior line, and prior systemic therapies, cell-of-origin, country, double/triple express, double/triple hit, drug formulation, most recent line, or stem cell transplant, prior radiotherapy, response to first line, sex, subgroup, subgroup analysis, subgroups, surgery, transformed DLBCL, World Health Organization (WHO) classification, }

Loncastuximab (ZYNLONTA) – Maximum Dose and Final Concentration

Medical Information

Product: Loncastuximab Tesirine

{concentration, Dilution, dosage, dose, dosing, max, maximum, overfill, reconstitution, }

Loncastuximab (ZYNLONTA) – Mechanism of Action

Medical Information

Product: Loncastuximab Tesirine

{mechanism, mechanism of action, mechanisms, MOA, }

Loncastuximab (ZYNLONTA) – Nausea and Vomiting Incidence

Medical Information

Product: Loncastuximab Tesirine

{antiemetic, chemotherapy induced nausea and vomiting, CINV, emesis, nausea, vomit, vomiting, }

Loncastuximab (ZYNLONTA) – Neutropenia Incidence

Medical Information

Product: Loncastuximab Tesirine

{adverse, AE, febrile, hematologic abnormalities, hematologic abnormality, neutropenia, neutrophil, reaction, reactions, TEAE, toxicities, toxicity, }

Loncastuximab (ZYNLONTA) – Pharmacokinetics

Medical Information

Product: Loncastuximab Tesirine

{conjugated antibody, distribution, excretion, free fraction, in vitro, metabolism, pharmacokinetic, pharmacokinetics, pharmacology,, PK, plasma protein, plasma protein bound. absorption, serum, serum levels, SG3199, total antibody, }

Loncastuximab (ZYNLONTA) – Premedication

Medical Information

Product: Loncastuximab Tesirine

Loncastuximab (ZYNLONTA) – Prior & Post Radiation Use

Medical Information

Product: Loncastuximab Tesirine

{radiation, radiation therapy, radiotherapy, }

Loncastuximab (ZYNLONTA) – Prophylactic Use of Growth Factors

Medical Information

Product: Loncastuximab Tesirine

{G-CSF, granulocyte colony stimulating factor, growth factor, prophylaxis, }

Loncastuximab (ZYNLONTA) – Rationale for Dose Selection

Medical Information

Product: Loncastuximab Tesirine

{AUC, DLT, dose, dose-escalation, dose-expansion, dose-limiting, dose-selection, maximum tolerated, MTD, }

Loncastuximab (ZYNLONTA) – Reinitiation of Therapy after a Missed Cycle

Medical Information

Product: Loncastuximab Tesirine

{dosage, dose, dose delay, dose interruption, dosing, missed cycle, missed dose, }

Loncastuximab (ZYNLONTA) – Renal Safety and PTLD

Medical Information

Product: Loncastuximab Tesirine

{adverse, AE, anuria, bladder, creatinine, disorders, dysuria, hematuria, hydronephrosis, incontinence, nocturia, pollakiuria, proteinuria, reaction, renal, retention, spasm, TEAE, ureterolithiasis, urinary, }

Loncastuximab (ZYNLONTA) – Richter’s Transformation Incidence

Medical Information

Product: Loncastuximab Tesirine

{incidence of richters, richers, richters transformation, }

Loncastuximab (ZYNLONTA) – Skin Reactions

Medical Information

Product: Loncastuximab Tesirine

{Artificial light, Cutaneous, Dermatologic, Erythema, Hyperpigmentation, Maculopapular, nail, photosensitivity, Pruritis, Rash, Skin, Sunlight, telangiectasia, }

Loncastuximab (ZYNLONTA) – Specific Gravity

Medical Information

Product: Loncastuximab Tesirine

{density, specific gravity, }

Loncastuximab (ZYNLONTA) – Stability with Alternative Dilution

Medical Information

Product: Loncastuximab Tesirine

{0.05, 50 mL,100 mL, closed system transfer device, cstd, D5W, Dextrose, Dextrose for injection, Dextrose in water, Dilution, Filter, In-line filter, IV bag, Lactated ringer, lactated ringers, Normal saline, NS, osmolality, PAB, Partial additive bag, pH, PO, Polyolefin, Polyvinylchloride, PVC, Ringer, }

Loncastuximab (ZYNLONTA) – Storage and Stability of Vials

Medical Information

Product: Loncastuximab Tesirine

{Dilution, excursion, handling, reconstitution, refrigerate, refrigerated, stability, storage, store, temperature, temperature cycling, vials, }

Loncastuximab (ZYNLONTA) – Subsequent CAR-T Therapy

Medical Information

Product: Loncastuximab Tesirine

Loncastuximab (ZYNLONTA) – Temperature Excursion Data

Medical Information

Product: Loncastuximab Tesirine

{Dilution, excursion, handling, integrity, reconstitution, refrigerate, refrigerated, ship, shipping, stability, storage, store, temperature, temperature cycling, }

Loncastuximab (ZYNLONTA) – Thrombocytopenia Incidence

Medical Information

Product: Loncastuximab Tesirine

{hematologic abnormalities, hematologic abnormality, Platelet, Platelet count, Platelet decrease, Platelet transfusion, Thrombocytopenia, }

Loncastuximab (ZYNLONTA) – Tumor Lysis Syndrome Incidence

Medical Information

Product: Loncastuximab Tesirine

{Incidence of Tumor, Tumor lysis, tumor lysis syndrome, }

Loncastuximab (ZYNLONTA) – Use Before or After Stem Cell Transplant

Medical Information

Product: Loncastuximab Tesirine

{allogeneic, autologous, HCT, hematopoietic cell transplantation, SCT, stem cell, transplant, transplantation, }

Loncastuximab (ZYNLONTA) – Use in Elderly Patients

Medical Information

Product: Loncastuximab Tesirine

{age, elderly, older, }

Loncastuximab (ZYNLONTA) – Use in Overweight Obese Patients

Medical Information

Product: Loncastuximab Tesirine

{ABW, Adjusted body weight, BMI, body mass index, obese, obesity, weight-adjusted, weight-adjusted dose, }

Loncastuximab (ZYNLONTA) – Use in Patients with CNS

Medical Information

Product: Loncastuximab Tesirine

{brain, central nervous system, CNS, leptomeningeal, leptomeningeal disease, }

Loncastuximab (ZYNLONTA) – Use in Patients with Hepatic Impairment

Medical Information

Product: Loncastuximab Tesirine

Loncastuximab (ZYNLONTA) – Use in Patients with p53 Mutation

Medical Information

Product: Loncastuximab Tesirine

{mutate, mutated, mutation, mutations, p53, p53 mutations, }

Loncastuximab (ZYNLONTA) – Use in Patients with Renal Impairment

Medical Information

Product: Loncastuximab Tesirine

{creatinine, excreted, excretion, haemodialysis, hemodialysis, kidney, pharmacokinetic, pharmacokinetics, renal, renally, }

Loncastuximab (ZYNLONTA) – Use in Pregnancy and Lactation

Medical Information

Product: Loncastuximab Tesirine

{birth defect, birth defects, breast milk, breastfed, breastfeed, contraception, embryo, embryotoxic, embryotoxicity, fertility, fetal, fetus, genotoxic, genotoxicity, infertile, infertility, lactate, lactation, milk, miscarriage, pregnancy, pregnant, reproduction, reproductive, teratogenic, teratogenicity, }

Loncastuximab (ZYNLONTA) -Photosensitivity Rash Associated with Lonca Case Study

Medical Information

Product: Loncastuximab Tesirine

{blister, Cutaneous, mistry, photosentivity, Rash, rash vesicular, telangiectasia, }

Loncastuximab (ZYNLONTA)-Rationale for ABW Calculation

Medical Information

Product: Loncastuximab Tesirine

{ABW, Adjusted body weight, Body surface area, BSA, Calculated, Calculation, Dose calculation, }